BioSpace News Archive

Revolo Biotherapeutics (“Revolo” or the “Company”) today announced it will host a virtual KOL event on ‘1104, a first-in-class peptide for eosinophilic esophagitis (EoE) and allergen sensitivity on Tuesday, August 29, 2023, at 11:00 AM – noon ET.

Cocrystal Pharma, Inc. announces the selection of its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a potential oral therapy for norovirus.

I-Mab today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023.

Mersana Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal (PBI) product portfolio, to address acute medical conditions announced the publication of positive results from a clinical study of intranasal powder-based Epinephrine.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection.

Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporate developments.

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

UroGen Pharma Ltd. today announced that The Journal of Urology published data from the Phase 3 ATLAS trial for investigational agent UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), that demonstrated superiority to transurethral resection of bladder tumor surgery (TURBT) with a 55% reduction of risk for recurrence, progression, or death in patients who received UGN-102.